SuanFarma-Header SuanFarma-Header

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Lead Product(s): Bemcentinib

            Therapeutic Area: Infections and Infectious Diseases Product Name: BGB324

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: University Hospital Southampton

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable July 12, 2021

            Details:

            In total, 179 eligible patients were enrolled across both studies between May 2020 and March 2021, randomly allocated on an open-label basis to treatment with bemcentinib in addition to standard of care (SoC) compared to SoC alone.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Lead Product(s): Bemcentinib

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable June 02, 2020

            Details:

            Dosing has commenced in the UK Government-backed Phase II clinical trial assessing bemcentinib in hospitalised COVID-19 patients. Bemcentinib was selected as the first candidate to be tested as part of the ACcelerating COVID-19 Research & Development platform (ACCORD) study.